stoxline Quote Chart Rank Option Currency Glossary
Arena Pharmaceuticals, Inc. (ARNA)
99.99  0 (0%)    12-31 19:00
Open: 99.97
High: 100
Volume: 0
Pre. Close: 99.99
Low: 99.97
Market Cap: 0(M)
Technical analysis
2022-11-18 4:18:42 PM
Short term     
Mid term     
Targets 6-month :  116.79 1-year :  136.42
Resists First :  100 Second :  116.79
Pivot price 99.98
Supports First :  99.98 Second :  99.97
MAs MA(5) :  99.98 MA(20) :  99.98
MA(100) :  99.98 MA(250) :  96.02
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  66.6 D(3) :  66.6
RSI RSI(14): 78.9
52-week High :  100 Low :  48.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ARNA ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 100.09 - 100.58 100.58 - 101
Low: 98.78 - 99.36 99.36 - 99.85
Close: 99.14 - 100.02 100.02 - 100.78
Company Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Headline News

Tue, 18 Jan 2022
Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline - Nasdaq

Sat, 15 Jan 2022
Arena Pharmaceuticals Inc Shares Close in on 52-Week High - Market Mover - Nasdaq

Tue, 21 Dec 2021
Pfizer Acquires Arena At A 100% Premium (NASDAQ:ARNA) - Seeking Alpha

Mon, 13 Dec 2021
Pfizer to Buy Arena at 100% Premium in $6.7 Billion Deal - Bloomberg

Mon, 13 Dec 2021
Pfizer to Acquire Arena Pharmaceuticals - Business Wire

Tue, 27 Jul 2021
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out -248 (M)
Shares Float 0 (M)
Held by Insiders 6.166e+007 (%)
Held by Institutions 6.152e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.1945e+008
EPS Est Next Qtrly -0.67
EPS Est This Year -2.95
EPS Est Next Year -2.74
Book Value (p.s.) -10.15
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 10 %
Return on Equity (ttm) 483.2 %
Qtrly Rev. Growth -70.4 %
Gross Profit (p.s.) -5.26
Sales Per Share 0
EBITDA (p.s.) -8.65
Qtrly Earnings Growth -5.4179e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -9.87
Price to Sales 166362
Price to Cash Flow 0
Stock Dividends
Dividend 6.02e+006
Forward Dividend 5.11e+006
Dividend Yield 6020600%
Dividend Pay Date 2017-06-18
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android